100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Publication number: 20140113873Abstract: Disclosed herein are methods of increasing epithelial cell proliferation (such as intestinal epithelial cell proliferation) by contacting epithelial cells with one or more CBPs. In some examples, the methods include administering the CBP to a subject, such as a subject in need of increased epithelial cell proliferation. Also disclosed herein are methods of identifying a subject having or at risk of developing hyperproliferation of epithelial cells (such as intestinal epithelial cells). Further disclosed are methods of decreasing epithelial cell proliferation by decreasing expression and/or activity of a CBP and methods of identifying inhibitors of epithelial cell proliferation and/or CBP activity.Type: ApplicationFiled: October 22, 2013Publication date: April 24, 2014Applicant: State of Oregon, Acting by and Through the State Board of Higher Education, on Behalf of theInventors: Karen Guillemin, Allison Banse
-
Patent number: 8703718Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: GrantFiled: March 12, 2013Date of Patent: April 22, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Patent number: 8703152Abstract: Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease. These method include administering to the subject a therapeutically effective dose of (i) an isolated AvrA protein or polypeptide fragment thereof or (ii) a nucleic acid molecule encoding the isolated AvrA protein or polypeptide fragment. Preferred inflammatory intestinal diseases include Inflammatory Bowel Disease, Celiac Disease, and gastroenteritis.Type: GrantFiled: June 3, 2009Date of Patent: April 22, 2014Assignee: University of RochesterInventor: Jun Sun
-
Patent number: 8703708Abstract: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.Type: GrantFiled: March 18, 2010Date of Patent: April 22, 2014Assignees: The Brigham and Women's Hospital, Inc., Cincinnati Children's Hospital Medical CenterInventors: Jeremy Duffield, Richard A. Lang
-
Patent number: 8703717Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.Type: GrantFiled: June 8, 2010Date of Patent: April 22, 2014Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Willem P. Stemmer, Nathan Geething, Jeffrey L. Cleland
-
Publication number: 20140107042Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.Type: ApplicationFiled: March 9, 2012Publication date: April 17, 2014Applicant: OMNI BIO PHARMACEUTICAL, INC.Inventors: James D. Crapo, A. Mario Q. Marcondes, H. Joachim Deeg
-
Publication number: 20140107014Abstract: The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.Type: ApplicationFiled: October 29, 2013Publication date: April 17, 2014Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Publication number: 20140105876Abstract: The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses.Type: ApplicationFiled: March 27, 2012Publication date: April 17, 2014Applicant: UNIVERSIDAD AUTONOMA DE OCCIDENTEInventors: Sandra Arce Guerrero, Carlos Humberto Valencia
-
Publication number: 20140099310Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: August 6, 2013Publication date: April 10, 2014Applicant: CELERA CORPORATIONInventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Patent number: 8691771Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: May 20, 2011Date of Patent: April 8, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20140093531Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicants: Fundacao Oswaldo Cruz (FIOCRUZ), The Government of the United States of America as represented by the Secretary of the Department ofInventors: Jesus G. Valenzuela, Jose M.C. Ribeiro, Aldina Barral, Manoel Netto, Claudia I. Brodskyn, Regis Gomes
-
Patent number: 8685932Abstract: Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The provided complexes include those in which the immunoglobulin portion binds to inhibitory Fc? receptors to a greater degree than to activating Fc? receptors. The provided complexes further include those in which the immunoglobulin portion bind to activating Fc? receptors to a greater degree than to inhibitory Fc? receptors. The complexes and compositions can be used for administration to subjects, such as for increasing immunity or decreasing inflammation, such as for treating diseases including autoimmune diseases and cancer.Type: GrantFiled: December 14, 2009Date of Patent: April 1, 2014Assignee: Option Pharmaceuticals, LLCInventor: Tod Lauerman
-
Patent number: 8685404Abstract: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain; or wherein the first domain is an MHC class I ?1 domain and the second domain is an MHC class I ?2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.Type: GrantFiled: January 30, 2012Date of Patent: April 1, 2014Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Jennifer Loftis, Marilyn Huckans, Arthur A. Vandenbark
-
Patent number: 8685403Abstract: Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling.Type: GrantFiled: January 29, 2010Date of Patent: April 1, 2014Assignee: The Regents of the University of CaliforniaInventors: Yoshikazu Takada, Jun Saegusa
-
Publication number: 20140088021Abstract: Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions.Type: ApplicationFiled: May 24, 2012Publication date: March 27, 2014Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Deborah H. Charych, Clark Norman Eid, Dennis G. Fry, Marina Konakova, Christine Frances Loehrlein
-
Publication number: 20140088019Abstract: Monovalent and multivalent multispecific complexes including ELP-MRD fusion proteins containing one or more modular recognition domains (MRDs) that bind target antigens are described. The use of these monovalent and multivalent multispecific complexes (e.g., ELP-MRD fusion proteins) in diagnostic, prognostic, and therapeutic applications and methods of making these complexes are also described.Type: ApplicationFiled: February 10, 2012Publication date: March 27, 2014Applicant: Zyngenia, Inc.Inventor: David M. Hilbert
-
Publication number: 20140086903Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: ApplicationFiled: March 15, 2013Publication date: March 27, 2014Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
-
Publication number: 20140086996Abstract: An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2.Type: ApplicationFiled: July 22, 2013Publication date: March 27, 2014Applicant: Kyushu University, National University CorporationInventors: Masahiro Goto, Noriho Kamiya, Yoshiro Tahara
-
Patent number: 8679480Abstract: A method and corresponding pharmaceutical composition to inhibit neuropathic pain by injecting intrathecally into a mammalian subject a neuropathic pain-inhibiting amount of a phosphatase falling within E.C. 3.1.3.x, more specifically a protein phosphatase falling within E.C. 3.1.3.16, and most specifically calcineurin.Type: GrantFiled: June 15, 2012Date of Patent: March 25, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Vjekoslav Miletic, Gordana Miletic
-
Patent number: 8673860Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: GrantFiled: February 3, 2010Date of Patent: March 18, 2014Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland
-
Patent number: 8673845Abstract: The method for transferring a foreign substance provided by the present invention includes the steps of: preparing a construct for transferring a foreign substance that contains a carrier peptide fragment including either the amino acid sequence WRRQARFK (SEQ ID NO. 1) or any amino acid sequence formed by the substitution, deletion, and/or addition (insertion) of 1, 2, or 3 amino acid residues in the amino acid sequence, and a foreign substance of interest that is bonded to the N-terminus and/or C-terminus of the carrier peptide fragment; supplying the construct for transferring a foreign substance to a test sample that contains a target eukaryotic cell; and incubating the test sample that has been supplied with the construct for transferring a foreign substance to thereby transfer the construct into the eukaryotic cell in the test sample.Type: GrantFiled: July 28, 2010Date of Patent: March 18, 2014Assignee: Toagosei Co., Ltd.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Mikio Niwa, Kenichi Tanaka
-
Patent number: 8673844Abstract: A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells. Also provided are pharmaceutical compositions for treating or preventing T-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells and a pharmaceutically-acceptable carrier.Type: GrantFiled: October 19, 2012Date of Patent: March 18, 2014Assignee: University of CincinnatiInventors: William Ridgway, David Erwin Adams, Kritika Kachapati
-
Patent number: 8673846Abstract: A cell proliferation promoter includes, as an active ingredient, an artificially synthesized peptide that includes (A) an amino acid sequence constituting a membrane-permeable peptide and (B) an amino acid sequence selected from SEQ ID NOs: 19 to 103 or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in the selected amino acid sequence.Type: GrantFiled: October 28, 2010Date of Patent: March 18, 2014Assignees: Toagosei Co. Ltd., Japan Tissue Engineering Co., Ltd.Inventors: Tetsuhiko Yoshida, Nahoko Kobayashi, Mikio Niwa, Chikara Shinohara, Masatoki Watanabe, Ken-ichiro Hata
-
Publication number: 20140065172Abstract: The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell. The present invention further relates to a pharmaceutical composition comprising said conjugate and to its use. The present invention also relates to a method of delivering a compound to a cell or an organism, preferably a patient.Type: ApplicationFiled: January 26, 2012Publication date: March 6, 2014Inventors: Christophe J. Echeverri, Birte Sönnichsen, Reinhard Wähler, Mike Werner Helms, Brian S. Sproat
-
Publication number: 20140056906Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
-
Publication number: 20140057858Abstract: The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.Type: ApplicationFiled: December 9, 2011Publication date: February 27, 2014Applicants: Inprenha Biotecnologia e Desenvolvimento Avancado Ltda-ME, UNIVERSIDADE DE SAO PAULO - USPInventors: Marcelo Dias Baruffi, Erika da Silva Carvalho Morani, Marcelo Roncoletta, Camillo del Cistia Andrade, Lilian Cataldi Rodrigues
-
Publication number: 20140057830Abstract: Alphabodies that specifically bind to cytokines or growth factor and/or their receptors, as well as polypeptides that comprise or essentially consist of such Alphabodies. Further nucleic acids encoding such Alphabodies; methods for preparing such Alphabodies and polypeptides; host cells expressing or capable of expressing such Alphabodies and polypeptides; compositions, and in particular pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells; and uses of such Alphabodies or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 6, 2012Publication date: February 27, 2014Applicant: COMPLIX SAInventors: Ignace Lasters, Johan Desmet, Maria Henderikx, Anita Wehnert, Geert Meersseman
-
Patent number: 8658596Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: September 14, 2010Date of Patent: February 25, 2014Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8658135Abstract: The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-? superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-? superfamily. The agent comprises the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for different sites on the same member or for different members of the TGF-? superfamily; at least two of bd1, bd2, bd3, and bd4 are different from each other.Type: GrantFiled: September 17, 2009Date of Patent: February 25, 2014Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes, Catherine Collins
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20140050714Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: ApplicationFiled: August 19, 2013Publication date: February 20, 2014Applicant: ORPHAZYME APSInventors: Thomas Kirkegaard Jensen, Marja H. Jaattela
-
Publication number: 20140050739Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20140050701Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symptoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: May 21, 2013Publication date: February 20, 2014Inventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20140051645Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: December 2, 2011Publication date: February 20, 2014Inventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
-
Patent number: 8653037Abstract: This invention provides novel truncation mutants of a phytochrome from the bacterium Deinococcus radiodurans. When expressed either in bacteria or mammalian cells, these mutant phytochromes spontaneously incorporate biliverdin, a ubiquitous intermediate in heme catabolism, and become fluorescent in the infrared (IR) region. These phytochromes are the first genetically encoded labels that can be excited by far-red light and fluorescent in the true IR (>700 nm). If these mutants instead incorporate protoporphyrin IX, an intermediate in heme biosynthesis, illumination now generates significant amounts of singlet oxygen. Singlet oxygen is useful because it can be used to kill individual proteins or cells, detect long-range protein-protein interactions, or generate electron-microscopic contrast. The invention also relates to methods of making and using such proteins and protein variants.Type: GrantFiled: June 11, 2009Date of Patent: February 18, 2014Assignees: The Centre National de la Recherche Scientifique, The Regents of the University of CaliforniaInventors: Xiaokun Shu, Antoine Royant, Roger Tsien
-
Publication number: 20140045756Abstract: The present disclosure relates to methods and compositions for modulating TNF and TNFR signaling. In particular, the disclosure describes methods and compositions for inhibiting TNF? signaling, such as in the prevention or treatment of TNF?-related diseases.Type: ApplicationFiled: March 9, 2012Publication date: February 13, 2014Applicant: New York UniversityInventor: Chuan-Ju Liu
-
Publication number: 20140044717Abstract: The invention is directed to a method for producing a polypeptide composition comprising: combining a polypeptide with a volatile additive to form a liquid mixture and lyophilizing the liquid mixture to obtain a lyophilized polypeptide composition.Type: ApplicationFiled: February 9, 2012Publication date: February 13, 2014Applicant: GLAXOSMITHKLINE LLCInventors: James Kranz, Joseph Rinella
-
Publication number: 20140045775Abstract: The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions.Type: ApplicationFiled: August 26, 2013Publication date: February 13, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Moshe Arditi, Pearl S. Gray
-
Publication number: 20140045760Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Fred HOFMANN, Jurgen Frevert
-
Patent number: 8648046Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: November 17, 2010Date of Patent: February 11, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Patent number: 8648044Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.Type: GrantFiled: September 24, 2010Date of Patent: February 11, 2014Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Etienne Baulieu, Beatrice Chambraud
-
Publication number: 20140038908Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.Type: ApplicationFiled: February 28, 2013Publication date: February 6, 2014Applicant: MT. SINAI HOSPITALInventors: Isabella Caniggia, Martin Post, Nima Soleymanlou, Andrea Jurisicova
-
Publication number: 20140038897Abstract: The invention refers to TFEB related molecules, as variants, mutants, truncated proteins, chimeras etc. that are constitutively localized in the nucleus of a eukaryote cell. Such molecules have a therapeutic applicability in all of disorders that need of an induction of the cell authophagic/lysosomal system, as lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases and metabolic diseases.Type: ApplicationFiled: March 7, 2012Publication date: February 6, 2014Applicant: FONDAZIONE TELETHONInventors: Andrea Ballabio, Carmine Settembre, Diego Luis Medina Sanabria
-
Publication number: 20140037661Abstract: The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy.Type: ApplicationFiled: February 8, 2012Publication date: February 6, 2014Applicant: PHADIA ABInventors: Alexandra Baar, Rudolf Valenta, Sandra Pahr, Bharani Srinivasan, Susanne Vrtala
-
Patent number: 8642557Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.Type: GrantFiled: March 11, 2011Date of Patent: February 4, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
-
Patent number: 8642733Abstract: Polypeptides that can elicit antibodies that bind to T-cell stimulating protein B (TspB) of N. meningitidis, and methods of use, are provided.Type: GrantFiled: November 4, 2010Date of Patent: February 4, 2014Assignee: Children's Hospital & Research Center OaklandInventor: Gregory R. Moe
-
Patent number: 8637013Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.Type: GrantFiled: March 21, 2012Date of Patent: January 28, 2014Assignee: The Regents of The University of MichiganInventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Cheng, Steve Kunkel
-
Patent number: 8637452Abstract: The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof.Type: GrantFiled: February 23, 2012Date of Patent: January 28, 2014Assignee: Massachusetts Institute of TechnologyInventors: Shuguang Zhang, Alexander Rich, Karolina Corin, Lotta T. Tegler
-
Patent number: 8637469Abstract: The invention describes a method of treating upper airway disease by administering a composition of one or more proinflammatory cytokine inhibitors sufficient to inhibit inflammation in the upper airways. The proinflammatory cytokines that are inhibited include TNF, IL-1 and IL-8. A medication dispensing unit which includes a container and a delivery system is used to administer the composition. The delivery system further encompasses a one-way valve, a microcatheter, or a liquid-pressure type sprayer.Type: GrantFiled: July 11, 2007Date of Patent: January 28, 2014Inventor: Roy Clifford Levitt
-
Patent number: 8633153Abstract: The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.Type: GrantFiled: February 26, 2009Date of Patent: January 21, 2014Assignee: Amgen Inc.Inventors: Kenneth William Walker, Fei Xiong